< 1 minute read
Sep. 17, 2021

CC-92480: an oral in vivo CRBN-based selective IKZF1/3 degrader

CC-92480

CRBN-based selective IKZF1/3 degrader oral efficacy in lenalidomide-resist. xenograft from phenotypic screen and optimization J. Med. Chem., Mar. 4, 2020 Celgene, San Diego, CA

drughunter.com
Drug Hunter Team
Loading...

twitterlinkedinemail

Other molecules you may be interested in